Targeting pheochromocytoma/paraganglioma with polyamine inhibitors

BACKGROUND: Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors that are mostly benign. Metastatic disease does occur in about 10% of cases of PCC and up to 25% of PGL, and for these patients no effective therapies are available. Patients with mutations in the succinate dehy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Metabolism
Main Authors: Rai, Sudhir Kumar, Bril, Fernando, Hatch, Heather M., Xu, Yiling, Shelton, Laura, Kalavalapalli, Srilaxmi, Click, Arielle, Lee, Douglas, Beecher, Chris, Kirby, Austin, Kong, Kimi, Trevino, Jose, Jha, Abhishek, Jatav, Shashank, Kriti, Kriti, Luthra, Soumya, Garrett, Timothy J., Guingab-Cagmat, Joy, Plant, Daniel, Bose, Prodip, Cusi, Kenneth, Hromas, Robert A., Tischler, Arthur S., Powers, James F., Gupta, Priyanka, Bibb, James, Beuschlein, Felix, Robledo, Mercedes, Calsina, Bruna, Timmers, Henri, Taieb, David, Kroiss, Matthias, Richter, Susan, Langton, Katharina, Eisenhofer, Graeme, Bergeron, Raymond, Pacak, Karel, Tevosian, Sergei G., Ghayee, Hans K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7482423/
https://ncbi.nlm.nih.gov/pubmed/32562798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.metabol.2020.154297
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados